Roundhill Russell 2000 0DTE Covered Call Strat ETF vs Recursion Pharmaceuticals Inc — how do they compare? Roundhill Russell 2000 0DTE Covered Call Strat ETF trades at $25.96 (market cap $159.33M), while Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.14B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 13.4× Roundhill Russell 2000 0DTE Covered Call Strat ETF's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Roundhill Russell 2000 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Roundhill Russell 2000 0DTE Covered Call Strat ETF for 53 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| RDTE | RXRX | |
|---|---|---|
Market Cap | $159.33M | $2.14B |
Volume | 248,058 | 30,789,535 |
Sector | Income / Options Overlay | Health |
52-Week High | $33.66 | $6.79 |
52-Week Low | $25.96 | $2.84 |
Typical Hold Time | 53 Days | 22 Days |
Enterprise Value | — | $1.66B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
RDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the Russell 2000 Index. The fund primarily holds a portfolio of short-term U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the Russell 2000. This highly tactical strategy aims to maximize premium capture by exploiting the high time decay of options that are expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on RDTE →Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →